We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KBR Wins EPC Contract From ExxonMobil to Expand Refinery
Read MoreHide Full Article
KBR, Inc. (KBR - Free Report) received a contract from ExxonMobil to deliver engineering, procurement and construction (“EPC”) services in order to enable the latter to move forward with its crude expansion project in Beaumont, TX. The deal is entitled to support refinery expansion of the offsite and interconnecting units. However, financial terms of the deal are not yet disclosed by the company.
KBR has been executing such projects safely and efficiently on the U.S. Gulf Coast over the past several years. In fact, it has successfully executed some of the world's largest and most technically complex projects. The recent deal will allow Hydrocarbons Services business to generate higher revenues.
Over the past few quarters, the company has been posting solid top-line numbers, backed by strong organic growth in Government Services and Technology businesses, accretive growth from Aspire and SGT, along with buoyant government contracting and hydrocarbons end-market results.
The company’s consulting business is experiencing increased activity, on the back of more efficient reutilization and strong pricing environment. In fact, KBR believes that it will notice strong Brownfield opportunities (especially in the consulting sector in the upstream area), largely attributable to rising commodity prices and underlying global demand.
Additionally, the company foresees decent opportunities in the downstream petrochemical and ethylene projects, along with various emerging small-scale LNG projects in North America that are expected to boost the segment’s overall performance. KBR anticipates persistent growth in the segment, with margins likely to come in the mid-20s in the near future.
Its contract winning spree underscores KBR's solid ability to safely and efficiently deliver projects in operating facilities. Notably, shares of the company have increased 19.5% in the past year, outperforming S&P 500’s growth of 0.6%.
Altair Engineering, Jacobs and Comfort Systems’ earnings for the current year are expected to increase 23.1%, 13.4% and 10%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
KBR Wins EPC Contract From ExxonMobil to Expand Refinery
KBR, Inc. (KBR - Free Report) received a contract from ExxonMobil to deliver engineering, procurement and construction (“EPC”) services in order to enable the latter to move forward with its crude expansion project in Beaumont, TX. The deal is entitled to support refinery expansion of the offsite and interconnecting units. However, financial terms of the deal are not yet disclosed by the company.
KBR has been executing such projects safely and efficiently on the U.S. Gulf Coast over the past several years. In fact, it has successfully executed some of the world's largest and most technically complex projects. The recent deal will allow Hydrocarbons Services business to generate higher revenues.
Over the past few quarters, the company has been posting solid top-line numbers, backed by strong organic growth in Government Services and Technology businesses, accretive growth from Aspire and SGT, along with buoyant government contracting and hydrocarbons end-market results.
The company’s consulting business is experiencing increased activity, on the back of more efficient reutilization and strong pricing environment. In fact, KBR believes that it will notice strong Brownfield opportunities (especially in the consulting sector in the upstream area), largely attributable to rising commodity prices and underlying global demand.
Additionally, the company foresees decent opportunities in the downstream petrochemical and ethylene projects, along with various emerging small-scale LNG projects in North America that are expected to boost the segment’s overall performance. KBR anticipates persistent growth in the segment, with margins likely to come in the mid-20s in the near future.
Its contract winning spree underscores KBR's solid ability to safely and efficiently deliver projects in operating facilities. Notably, shares of the company have increased 19.5% in the past year, outperforming S&P 500’s growth of 0.6%.
KBR, Inc. Price
KBR, Inc. price | KBR, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, KBR carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the Zacks Construction sector include Altair Engineering Inc. (ALTR - Free Report) , Jacobs Engineering Group Inc. and Comfort Systems USA, Inc. (FIX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Altair Engineering, Jacobs and Comfort Systems’ earnings for the current year are expected to increase 23.1%, 13.4% and 10%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>